<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00222664</url>
  </required_header>
  <id_info>
    <org_study_id>Qidong-HBV-Study</org_study_id>
    <nct_id>NCT00222664</nct_id>
  </id_info>
  <brief_title>Qidong Hepatitis B Intervention Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qidong Liver Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Institute for Therapeutic Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <brief_summary>
    <textblock>
      During 1983-1990 in the Jiangsu province of China, 80,000 infants were randomised by area of
      birth between control, standard Hepatitis B vaccination (at 0, 1 and 6 months of age) and
      standard vaccination plus a booster dose at about 2 to 3 years of age. The aim is to prevent
      establishment of chronic HBV infection in early childhood, hence to prevent the morbidity of
      chronic hepatitis B in young adolescents and the incidence/mortality several decades later
      from liver cancer and other HBV related chronic liver diseases. Long-term follow-up through
      central registries will determine the impact of vaccination on liver cancer incidence and
      mortality.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 1983</start_date>
  <completion_date>December 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>80000</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Liver Neoplasms</condition>
  <condition>Liver Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hep-V Vax</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        all infants born in Qidong between September 1983 and November 1990

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Zongtang Sun, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Peto, Msc</last_name>
    <role>Study Director</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qidong Liver Cancer Institute</name>
      <address>
        <city>Qidong</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Service Unit and Epidemiological Studies Unit</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Sun Z, Zhu Y, Stjernsward J, Hilleman M, Collins R, Zhen Y, Hsia CC, Lu J, Huang F, Ni Z, et al. Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study. Cancer Detect Prev. 1991;15(4):313-8.</citation>
    <PMID>1665400</PMID>
  </results_reference>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>September 13, 2005</last_update_submitted>
  <last_update_submitted_qc>September 13, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2005</last_update_posted>
  <keyword>hepatitis B</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>prevention</keyword>
  <keyword>vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

